We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Greiner Bio-One

Download Mobile App





Technopath Launches Multichem ID-COVID-19 Quality Control Solutions

By HospiMedica International staff writers
Posted on 19 May 2020
Print article
Image: Multichem ID-Covid 19 Quality Controls (Photo courtesy of Technopath Clinical Diagnostics)
Image: Multichem ID-Covid 19 Quality Controls (Photo courtesy of Technopath Clinical Diagnostics)
Technopath Clinical Diagnostics (Tipperary, Ireland) has launched its Multichem ID-COVID-19 Quality Control Solutions which offer laboratories third-party quality control products, enabling an independent, unbiased assessment of a diagnostic device or method for COVID-19 antibody testing.

Triggered by a massive effort from the clinical diagnostic industry to introduce antibody tests worldwide, Technopath is responding to the urgent need from the laboratory community for third-party quality control solutions. The company’s Multichem COVID-19 (IgG, IgM and Neg) solutions are third-party quality control products that help provide an independent assessment of a diagnostic device or method for COVID-19 antibody testing. These controls are manufactured based on a human base matrix that helps provide a product analogous to a patient sample.

"We are firmly resolute in supporting the global response to the COVID-19 pandemic by manufacturing independent quality solutions helping diagnostic companies and laboratories get to optimal test performance as quickly as possible," said Malcolm Bell, CEO and founder of Technopath. "With some clinical labs processing up to 500,000 coronavirus antibody tests per month, the company is laser-focused on assuring the quality of patient testing, and we believe our third-party QC solutions will reduce potential errors allowing laboratories to release patient results with confidence."

"With antibody testing accelerating across nations, clinical laboratories should be demanding data on validation studies, sensitivity and specificity, and conducting those studies in their labs," said James O. Westgard, PhD, longtime leader in clinical laboratory quality-control and founder of Westgard QC. "Quality-control is one of the most critical aspects of laboratory testing, and laboratories need to be adding third-party controls to their methods as soon as possible."


Print article
Radcal

Channels

Copyright © 2000-2020 Globetech Media. All rights reserved.